Advice

Efalizumab (Raptiva) for the treatment of moderate to severe chronic plaque psoriasis

In Feb 2009 the European Medicines Agency suspended the marketing authorisation for this product across the EU due to safety concerns.

The SMC Advice has been removed from the website.

Medicine details

Medicine name:
Efalizumab (Raptiva®)
SMC ID:
146/04
Indication:
Moderate to severe chronic plaque psoriasis
Pharmaceutical company
Serono Ltd
BNF chapter
Skin
Submission type
Full
Status
Withdrawn
Date advice published
10 January 2005
Additional notes

NICE MTA Advice:  SMC Advice is superseded by National Institute for Health and Clinical Excellence (NICE) Multiple Technology Appraisal (MTA)

In February 2009 the European Medicines Agency completed a review of efalizumab (Raptiva) after concerns about its safety .The Agency’s Committee for Medicinal Products for Human Use (CHMP) concluded that the benefits of efalizumab do not outweigh its risks and that the Marketing Authorisation should be suspended across the EU.